Feedback
Settings

Settings

Goto Application

1. WO2003007933 - NAPTHOQUINONE DERIVATIVES AS INHIBITORS OF TAU AGGREGATION FOR THE TREATMENT OF ALZHEIMER'S AND RELATED NEURODEGENERATIVE DISORDERS

PermaLink
Publication Number WO/2003/007933
Publication Date 30.01.2003
International Application No. PCT/GB2002/003269
International Filing Date 16.07.2002
Chapter 2 Demand Filed 05.02.2003
IPC
A61K 31/122 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
122having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/255 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
255of sulfoxy acids or sulfur analogues thereof
CPC
A61K 31/122
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
122having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/255
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
255of sulfoxy acids or sulfur analogues thereof
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
16Anti-Parkinson drugs
Applicants
  • THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN [GB]/[GB] (AllExceptUS)
  • WISCHIK, Claude, Michel [FR]/[GB] (UsOnly)
  • HORSLEY, David [GB]/[GB] (UsOnly)
  • RICKARD, Janet, Elizabeth [GB]/[GB] (UsOnly)
  • HARRINGTON, Charles, Robert [GB]/[GB] (UsOnly)
Inventors
  • WISCHIK, Claude, Michel
  • HORSLEY, David
  • RICKARD, Janet, Elizabeth
  • HARRINGTON, Charles, Robert
Agents
  • KREMER, Simon, M.
Priority Data
0117326.916.07.2001GB
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) NAPTHOQUINONE DERIVATIVES AS INHIBITORS OF TAU AGGREGATION FOR THE TREATMENT OF ALZHEIMER'S AND RELATED NEURODEGENERATIVE DISORDERS
(FR) DERIVES DE NAPTHOQUINONE EN TANT QU'INHIBITEURS DE L'AGREGATION DES TAU POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER ET DES TROUBLES DE NEURODEGENERESCENCE ASSOCIES
Abstract
(EN) Provided are napthoquinone-type compounds which can be used to modulate the aggregation of protein (e.g. tau) associated with neurodegenerative disease (e.g. Alzheimer's disease). Structure-function characteristics for oxidised and reduced napthoquinone-type compounds, such as menadione-related compounds, are disclosed. The invention further provides methods of treatment or prophylaxis of neurodegenerative diseases and/or clinical dementias based on the compounds.
(FR) La présente invention concerne des composés de type napthoquinone qui peuvent être utilisés pour moduler l'agrégation de protéines (par ex. tau) associées à des troubles de neurodégénérescence (par ex. la maladie d'Alzheimer). Cette invention concerne également des caractéristiques structure-fonction pour des composés de type napthoquinone oxydée ou réduite. L'invention a également pour objet des procédés destinés au traitement ou à la prévention de troubles de neurodégénérescence et/ou des démences cliniques se basant sur les composés.
Related patent documents
SG148846
EP1408952
CN1553800
CA2451422
AU2002317354
ES2287292
DE000060219917
JP2004534854
AT361067
SG2004000840
IN157/KOLNP/2004This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
US20050107472
Latest bibliographic data on file with the International Bureau
# -